Tao Xie1, Hailin Ding2, Mingfeng Xia3, Xiaobiao Zhang4,5,6, Wei Sun7, Tengfei Liu1, Ye Gu1, Chongjing Sun1, Fan Hu1. 1. Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, China. 2. Department of Emergency, Zhongshan Hospital, Fudan University, Shanghai, China. 3. Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. 4. Department of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, China. xiaobiao_zhang@163.com. 5. Digital Medical Research Center, Zhongshan Hospital, Fudan University, Shanghai, China. xiaobiao_zhang@163.com. 6. Shanghai Key Laboratory of Medical Image Computing and Computer-Assisted Intervention, Shanghai, China. xiaobiao_zhang@163.com. 7. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Abstract
PURPOSE: Acromegaly is a systemic metabolic disease. Growth hormone (GH) have a significant impact on adipose tissue (AT). A huge reduction of serum GH after surgical treatment may cause substantial AT redistribution. The objective of this study was to illustrate the dynamic changes in distribution of facial and abdominal AT correlated with surgical treatment in patients with acromegaly. METHODS: Abdominal AT in 17 acromegaly patients (group 1) was studied longitudinally preoperatively and 1 month to 1 year postoperatively. The facial and abdominal subcutaneous AT (fSAT and aSAT) of another 17 acromegaly patients (group 2) were compared with 7 nonfunctional pituitary adenoma (NFPA) controls. The areas of fSAT, aSAT, and visceral adipose tissue (VAT) were obtained by MRI and quantified by image analysis software, and intrahepatic lipid (IHL) was assessed by 1H magnetic resonance spectroscopy (MRS). RESULTS: Abdominal adipose tissue (aSAT, VAT, and IHL) increased overall after surgical treatment. However, IHL first decreased and then continuously increased during the follow-up. Compared with the increased amount of aSAT, the fSAT amount decreased after surgical treatment. The inconsistency of this phenomenon did not appear in the NFPA control subjects. CONCLUSION: The perioperative dynamic distribution of the facial and abdominal fat in acromegaly revealed regional differences in the intricate effect of GH on adipose tissue. Reduction of serum GH after surgical treatment of acromegaly was associated with dynamic increases of IHL, abdominal visceral, and subcutaneous fat, but a reduction of facial subcutaneous fat.
PURPOSE:Acromegaly is a systemic metabolic disease. Growth hormone (GH) have a significant impact on adipose tissue (AT). A huge reduction of serum GH after surgical treatment may cause substantial AT redistribution. The objective of this study was to illustrate the dynamic changes in distribution of facial and abdominal AT correlated with surgical treatment in patients with acromegaly. METHODS: Abdominal AT in 17 acromegalypatients (group 1) was studied longitudinally preoperatively and 1 month to 1 year postoperatively. The facial and abdominal subcutaneous AT (fSAT and aSAT) of another 17 acromegalypatients (group 2) were compared with 7 nonfunctional pituitary adenoma (NFPA) controls. The areas of fSAT, aSAT, and visceral adipose tissue (VAT) were obtained by MRI and quantified by image analysis software, and intrahepatic lipid (IHL) was assessed by 1H magnetic resonance spectroscopy (MRS). RESULTS: Abdominal adipose tissue (aSAT, VAT, and IHL) increased overall after surgical treatment. However, IHL first decreased and then continuously increased during the follow-up. Compared with the increased amount of aSAT, the fSAT amount decreased after surgical treatment. The inconsistency of this phenomenon did not appear in the NFPA control subjects. CONCLUSION: The perioperative dynamic distribution of the facial and abdominal fat in acromegaly revealed regional differences in the intricate effect of GH on adipose tissue. Reduction of serum GH after surgical treatment of acromegaly was associated with dynamic increases of IHL, abdominal visceral, and subcutaneous fat, but a reduction of facial subcutaneous fat.
Authors: Carlos M Reyes-Vidal; Hamed Mojahed; Wei Shen; Zhezhen Jin; Fernando Arias-Mendoza; Jean Carlos Fernandez; Dympna Gallagher; Jeffrey N Bruce; Kalmon D Post; Pamela U Freda Journal: J Clin Endocrinol Metab Date: 2015-06-02 Impact factor: 5.958
Authors: Miriam A Bredella; Melanie Schorr; Laura E Dichtel; Anu V Gerweck; Brian J Young; Whitney W Woodmansee; Brooke Swearingen; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2017-11-01 Impact factor: 5.958
Authors: Michael Madsen; Thomas Krusenstjerna-Hafstrøm; Louise Møller; Britt Christensen; Mikkel Holm Vendelbo; Steen B Pedersen; Jan Frystyk; Niels Jessen; Troels Krarup Hansen; Hans Stødkilde-Jørgensen; Allan Flyvbjerg; Jens Otto L Jørgensen Journal: J Clin Endocrinol Metab Date: 2012-02-01 Impact factor: 5.958
Authors: Darlene E Berryman; Edward O List; Lucila Sackmann-Sala; Ellen Lubbers; Rachel Munn; John J Kopchick Journal: Growth Horm IGF Res Date: 2011-04-05 Impact factor: 2.372
Authors: A Tominaga; K Arita; K Kurisu; T Uozumi; K Migita; K Eguchi; K IIda; H Kawamoto; T Mizoue Journal: Endocr J Date: 1998-06 Impact factor: 2.349
Authors: Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal Journal: Hepatology Date: 2003-06 Impact factor: 17.425
Authors: Angelina Passaro; Maria Agata Miselli; Juana Maria Sanz; Edoardo Dalla Nora; Mario Luca Morieri; Rossella Colonna; Rado Pišot; Giovanni Zuliani Journal: BMC Genomics Date: 2017-02-23 Impact factor: 3.969